Equity Analysis /
United States of America

US : Bristol-Myers Squibb Company - BMY | Updating Model for Full-Year Outlook and Commentary on 1H21 Catalysts

    Bowen Wu
    Bowen Wu

    Res. Assoc.

    Follow
    CGS-CIMB
    20 January 2021
    Published byCGS-CIMB

    We have updated our BMY model to account for recent guidance from management. We have made minor changes to drug launch timing along with reflecting use of cash flow that had been previously held for the CELG CVR. Our 1H2021 catalyst outlook remains focused on the first presentation of deucravaciti